Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07688772RecruitingPhase 3
Study of SHR-1819 Injection for Seasonal Allergic Rhinitis
This trial tests a new injection called SHR-1819 for people with seasonal allergies who haven't responded well to standard treatments like nasal sprays or antihistamines. It aims to see if it can reduce allergy symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07693751RecruitingPhase 1/Phase 2
Testing a new drug for advanced colorectal cancer
This trial tests a new drug called SOT109 for people with advanced colorectal cancer that can't be removed by surgery or has spread. The goal is to see if it is safe, how well it works, and how the body handles it.
Houston, TexasAges 18 years+ - NCT07695207RecruitingPhase 3
Testing SMZ1 with ranibizumab for wet macular degeneration
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
Seoul, SeoulAges 50 years+ - NCT06017362RecruitingPhase 4
Insulin drops for dry eye in glaucoma patients
This study tests whether insulin eye drops can safely help dry eye in people who also use eye drops for glaucoma. It may offer a new option if you have both conditions and your eye pressure is stable.
Madrid, MadridAges 18 years+ - NCT06652906RecruitingPhase 2
A bowel prep study for people aged 50 to 70
This study tests a sodium phosphate powder for cleaning the bowel before a colonoscopy. It looks at how safe and effective it is for people in this age group.
Shanghai, Shanghai MunicipalityAges 50–70 - NCT07688928Recruiting
Finerenone vs spironolactone for high blood pressure from aldosteronism
This trial compares two medicines, finerenone and spironolactone, to see which works better and is safer for lowering blood pressure in people with primary aldosteronism. It may help you if you have high blood pressure caused by too much aldosterone.
DhakaAges 18 years+ - NCT07689578RecruitingPhase 4
Testing a new immunotherapy for chronic kidney transplant rejection
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Chengdu, SichuanAges 18 years+ - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT07689188RecruitingPhase 2
Roflumilast foam for hidradenitis suppurativa in teens and adults
This study tests a foam medication (roflumilast 0.3%) applied to the skin to see if it safely reduces hidradenitis suppurativa (HS) bumps and pain in teens and adults. It might help people with mild-to-moderate HS, especially those who haven't tried this foam before.
Missouri City, TexasAges 12 years+ - NCT07693075RecruitingPhase 2
Radiotherapy for high-risk prostate cancer with boost to tumor
This trial tests a special type of radiation therapy that gives a higher dose to the tumor while treating the whole prostate. It is for men with high-risk or very high-risk prostate cancer that has not spread to distant organs.
CairoAges 18 years+ - NCT06655662RecruitingPhase 1
Gene therapy for severe beta-thalassemia
This trial tests a one-time gene therapy using your own blood stem cells to treat severe beta-thalassemia. It may help you stop needing regular blood transfusions.
GuangxiAges 6–35 - NCT06656624RecruitingPhase 2
Ribociclib plus hormone therapy for advanced breast cancer
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Nanjing, JiangsuAges 18–99 - NCT06659653RecruitingEarly Phase 1
PRG-2302 for relapsed or hard-to-treat B-cell acute lymphoblastic leukemia
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
Jinzhou, HubeiAges 18–70 - NCT05410925RecruitingPhase 4
Half-dose r-SAK before heart stent procedure for heart attack
This trial tests whether a half-dose medicine called r-SAK given before a primary PCI heart stent procedure improves outcomes and safety in people with a specific type of heart attack. It may help the heart recover better, but it also checks the risk of side effects like bleeding.
Nanjing, JiangsuAges 18–75 - NCT05927428RecruitingPhase 2
Eye drops for neurotrophic corneal ulcers
This Phase 2 trial tests BRM424 eye drops in adults with neurotrophic keratitis (a weakened, slow-healing cornea) to see if they help and are safe over 28 days. You may be able to join if your condition matches Stage 2 or Stage 3 and you meet the safety rules.
Leland, North CarolinaAges 18 years+ - NCT07682506RecruitingPhase 3
Testing a new vitiligo ointment for face and body patches
This trial tests an ointment called MH004 to see if it helps repigment white patches in people with non-segmental vitiligo (the most common type). It focuses on patches on the face and body.
Beijing, Beijing MunicipalityAges 12–75 - NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
SeoulAges 1–25 - NCT07683325RecruitingPhase 2
Study of ontunisertib for fibrostenosing Crohn's disease
This trial tests an investigational drug called ontunisertib versus a placebo in people with Crohn's disease that has caused narrowing (strictures) in the small intestine. It aims to see if the drug can help without needing surgery or other procedures.
Bradenton, FloridaAges 18 years+ - NCT07686679RecruitingPhase 4
A study of DA-9701 for functional dyspepsia
This trial tests a drug called DA-9701 to see if it can help people with functional dyspepsia, a condition where you have stomach pain or discomfort without a clear physical cause. It aims to improve your digestive symptoms.
SeoulAges 19–75 - NCT07680946RecruitingPhase 2
Testing ublituximab for treatment-resistant schizophrenia
This trial tests an experimental drug, ublituximab, to see if it helps people with schizophrenia that hasn't gotten better with standard treatments. It may offer a new option for those who still have significant symptoms despite current therapy.
Little Rock, ArkansasAges 18–60 - NCT07686081RecruitingPhase 3
Testing ponesimod for moderate to severe ulcerative colitis
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
Chula Vista, CaliforniaAges 18–75 - NCT06660511RecruitingEarly Phase 1
Combination therapy for HER2-positive platinum-resistant ovarian cancer
This trial tests a combination of two drugs—Disitamab Vedotin and Anlotinib—for patients with ovarian cancer that has come back after platinum chemotherapy. It is designed for people whose tumors show a specific protein called HER2, and it aims to see if the combination is safe and effective.
Changsha, HunanAges 18 years+ - NCT06660992RecruitingPhase 3
Study of HSK31858 for non-CF bronchiectasis
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
Guangzhou, GuangdongAges 18 years+ - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.